ISTA Pharma accepts subpoena on Xibrom promotion
California, USA-based ISTA Pharmaceuticals says that it has received a subpoena from the US Attorney's Office in Buffalo, New York, requesting the production of documents regarding promotional, educational and other activities relating to Xibrom (bromfenac sodium ophthalmic solution) 0.09%.
The firm says its policy is to fully comply with all applicable US and foreign laws, rules and regulations of governmental agencies or other authorities. In particular, the company's code of conduct and legal compliance statutes are intended to ensure full compliance with all laws, rules and regulations governing the sale and marketing of pharmaceutical products. ISTA plans to fully cooperate in responding to the subpoena.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze